Fenebrutinib in PPMS: Insights from ACTRIMS Forum 2026
From The ECTRIMS Podcast by The European Committee for Treatment and Research in Multiple Sclerosis
February 7, 2026 · 34 min
About this episode
This episode discusses the potential of fenebrutinib as a treatment for primary progressive multiple sclerosis based on recent clinical trial results.
Clinical trial results unveiled today at ACTRIMS Forum 2026 suggest that fenebrutinib may be a novel and effective treatment option for people living with primary progressive multiple sclerosis. In this exclusive episode providing the first expert discussion of the complete dataset, FENtrepid trial leads Prof. Amit Bar-Or (University of Pennsylvania) and Dr. Stephen Hauser (University of California San Francisco) break down what the fenebrutinib results really show. Together, they explore: Why BTK inhibition is uniquely positioned to address progressive MS biology How fenebrutinib compared to ocrelizumab in the Phase 3 FENtrepid PPMS trial What the data suggest for patients with non-relapsing, chronic disease Listen for a deep dive into the science and the clinical implications. Editorial Note: At 21:49, the discussion refers to Müller cells. The correct term is Kupffer cells. Download the transcript
People in this episode
Guests: Prof. Amit Bar-Or, Dr. Stephen Hauser
Topics covered
- primary progressive multiple sclerosis
- fenebrutinib
- clinical trial results
- BTK inhibition
- FENtrepid trial
- progressive MS biology
- treatment options
Keywords
- fenebrutinib
- primary progressive multiple sclerosis
- clinical trials
- BTK inhibition
- FENtrepid trial
- ocrelizumab
- ACTRIMS Forum 2026
Mentioned in this episode
Organizations: University of Pennsylvania, University of California San Francisco
Products: fenebrutinib, ocrelizumab
Books & works: FENtrepid trial
More episodes of The ECTRIMS Podcast
- Fenebrutinib in Relapsing MS: FENhance Trial Results Explained · April 22, 2026 · 26 min
- How MRI and OCT are Changing Multiple Sclerosis Diagnosis, Prognosis, and Treatment · April 8, 2026 · 25 min
- Does the Label Given to My MS Disease Course Matter? · March 19, 2026 · 24 min
- Rehabilitation in MS and the Case for Early Intervention · February 25, 2026 · 22 min
- Harnessing the Gut Microbiome in MS: From Insight to Intervention · January 13, 2026 · 33 min
- How well are we measuring cognition in MS? · December 8, 2025 · 30 min
Explore listener stats, chart rankings, contacts and more on the The ECTRIMS Podcast podcast page.